title: Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases.
abstract: Oxygen concentration in prostate cancer tissue is significantly low, i.e. ~0.3% O2. This study showed that pathological hypoxia (<0.5% O2) increased the expression of androgen receptor (AR) target genes such as prostate-specific antigen (PSA) and kallikrein-related peptidase 2 in LNCaP human prostate cancer cells by modifying the quantity and activity of related Jumonji C domain-containing histone demethylases (JMJDs). Under pathological hypoxia, the catalytic activities of JMJD2A, JMJD2C and Jumonji/ARID domain-containing protein 1B (JARID1B) were blocked due to the lack of their substrate, i.e. oxygen. Chromatin immunoprecipitation analyses showed that hypoxia increased the appearance of H3K9me3 and H3K4me3, substrates of JMJD2s and JARID1B, respectively, in the PSA enhancer. In contrast, JMJD1A, which demethylates both H3K9me2 and H3K9me1, maintained its catalytic activity even under severe hypoxia. Furthermore, hypoxia increased the expression of JMJD1A. Hypoxia and androgen additively increased the recruitment of JMJD1A and p300 on the enhancer region of PSA through interaction with the hypoxia-inducible factor-1α and AR, both of which bind the PSA enhancer. Thus, hypoxia enhanced the demethylation of H3K9me2 and H3K9me1, leading to provide unmethylated H3K9 residues that are substrates for histone acetyltransferase, p300. Consequently, hypoxia increased the acetylation of histones of the PSA enhancer, which facilitates its transcription.
authors.affiliation: Department of Life Science, University of Seoul, Siripdae-gil 13, Dongdaemun-gu, Seoul 130-743, Korea and.
authors.forename: Ho-Youl
authors.initials: HY
authors.lastname: Lee
authors.forename: Eun Gyeong
authors.initials: EG
authors.lastname: Yang
authors.forename: Hyunsung
authors.initials: H
authors.lastname: Park
mesh_terms: D000107:Acetylation; D002384:Catalysis; D045744:Cell Line, Tumor; D051548:Histone Acetyltransferases / Q000235:genetics*; D006657:Histones / Q000235:genetics; D006801:Humans; D000860:Hypoxia / Q000235:genetics*; D047908:Intracellular Signaling Peptides and Proteins; D056484:Jumonji Domain-Containing Histone Demethylases / Q000235:genetics*; D007610:Kallikreins / Q000235:genetics; D008297:Male; D024101:Mitochondrial Proteins; D009363:Neoplasm Proteins / Q000235:genetics; D009687:Nuclear Proteins / Q000235:genetics; D017430:Prostate-Specific Antigen / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics; D011944:Receptors, Androgen / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics; D015854:Up-Regulation / Q000235:genetics; D050880:p300-CBP Transcription Factors / Q000235:genetics; D000099224:p300-CBP-Associated Factor
chemical_list: D051548:Histone Acetyltransferases; D006657:Histones; D047908:Intracellular Signaling Peptides and Proteins; D056484:Jumonji Domain-Containing Histone Demethylases; D007610:Kallikreins; D024101:Mitochondrial Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D017430:Prostate-Specific Antigen; D011944:Receptors, Androgen; D012097:Repressor Proteins; D050880:p300-CBP Transcription Factors; D000099224:p300-CBP-Associated Factor; C410798:AR protein, human; C405619:HIGD1A protein, human; C413655:KDM4C protein, human; C119611:KDM5B protein, human; C494424:KDM4A protein, human